Feed aggregator

Boehringer Ingelheim Aims to Bring 25 New Products to Market by 2030

Biospace news - Tue, 04/16/2024 - 02:00
Boehringer Ingelheim Aims to Bring 25 New Products to Market by 2030 4/16/2024

Novartis Secures Phase III Fabhalta Win in IgAN as FDA Starts Priority Review

Biospace news - Tue, 04/16/2024 - 02:00
Novartis Secures Phase III Fabhalta Win in IgAN as FDA Starts Priority Review 4/16/2024

Intra-Cellular Touts Phase III Major Depressive Disorder Results for Antipsychotic Drug

Biospace news - Tue, 04/16/2024 - 02:00
Intra-Cellular Touts Phase III Major Depressive Disorder Results for Antipsychotic Drug 4/16/2024

Ultragenyx Eyes Pivotal Study After Mid-Stage Win in Angelman Syndrome

Biospace news - Tue, 04/16/2024 - 02:00
Ultragenyx Eyes Pivotal Study After Mid-Stage Win in Angelman Syndrome 4/16/2024

Pfizer, BioNTech Get Legal Pause in Moderna’s COVID-19 Vaccine Patent Lawsuit

Biospace news - Tue, 04/16/2024 - 02:00
Pfizer, BioNTech Get Legal Pause in Moderna’s COVID-19 Vaccine Patent Lawsuit 4/16/2024

Next-generation treatments hitch a ride into cancer cells

World Pharma News - Mon, 04/15/2024 - 10:00
Antisense oligonucleotides (ASOs) are next-generation drugs that can treat disease by blocking the transfer of harmful messages from our genes. In people with cancer, ASOs have the potential to block messages that encourage the growth and spread of the tumor. However, ASOs aren’t used for treating cancer yet. They must first get delivered inside cancer cells, but the cancer cells won’t let them in.

Finding an effective ASO delivery system is a major challenge. Cancer cells have gatekeeper molecules that stop unwanted substances from entering.

FDA Puts Clinical Hold on Neumora’s Schizophrenia Drug Due to Preclinical Saf...

Biospace news - Mon, 04/15/2024 - 02:00
FDA Puts Clinical Hold on Neumora’s Schizophrenia Drug Due to Preclinical Saf... 4/15/2024

Roche Bispecific T Cell Engager Improves Survival in Lymphoma, Teeing up Label Expansion

Biospace news - Mon, 04/15/2024 - 02:00
Roche Bispecific T Cell Engager Improves Survival in Lymphoma, Teeing up Label Expansion 4/15/2024

FDA Adcomm Backs New Surrogate Endpoint for Accelerated Approvals in Blood Cancer

Biospace news - Mon, 04/15/2024 - 02:00
FDA Adcomm Backs New Surrogate Endpoint for Accelerated Approvals in Blood Cancer 4/15/2024

AbbVie Touts Long-Term Efficacy of Qulipta as Preventive Migraine Treatment

Biospace news - Mon, 04/15/2024 - 02:00
AbbVie Touts Long-Term Efficacy of Qulipta as Preventive Migraine Treatment 4/15/2024

Genentech Walks Away From $3B Allogeneic T-Cell Pact with Adaptimmune

Biospace news - Mon, 04/15/2024 - 02:00
Genentech Walks Away From $3B Allogeneic T-Cell Pact with Adaptimmune 4/15/2024

Regeneron Launches $500M Venture Capital Fund Skewed Toward Biotech

Biospace news - Mon, 04/15/2024 - 02:00
Regeneron Launches $500M Venture Capital Fund Skewed Toward Biotech 4/15/2024

Listen Up: Emerging Vocal Biomarker Could Aid ALS Drug Development

Biospace news - Mon, 04/15/2024 - 02:00
Listen Up: Emerging Vocal Biomarker Could Aid ALS Drug Development 4/15/2024

5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffra

Biospace news - Mon, 04/15/2024 - 02:00
5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffra 4/15/2024

4 Investigational Weight Loss Drugs That Could Change the Market

Biospace news - Mon, 04/15/2024 - 02:00
4 Investigational Weight Loss Drugs That Could Change the Market 4/15/2024

Groundbreaking treatment approach shows promise in hard-to-treat cancers

World Pharma News - Fri, 04/12/2024 - 10:00
Researchers have developed a functional precision medicine approach that targets cancer by combining genetic testing with a new way to test individual drugs on tumor samples. The results of the clinical study were published today in Nature Medicine.

This combined approach, developed by Florida International University cancer researcher Diana Azzam, was used successfully for the first time to guide treatment of relapsed pediatric cancer patients in collaboration with First Ascent Biomedical and Dr. Maggie Fader at the Helen & Jacob Shaham Cancer & Blood Disorders Institute at Nicklaus Children's Hospital in Miami.

This outdated diabetes drug still has something to offer

World Pharma News - Thu, 04/11/2024 - 10:00
Thiazolidinediones (TZDs) are a class of drug that can be used to treat type 2 diabetes by reversing insulin resistance, one of the main hallmarks of the disease. While TZDs were extremely popular in the 1990’s and early 2000’s, they have fallen out of use among physicians in recent decades because they were discovered to cause unwanted side effects, including weight gain and excess fluid accumulation in body tissues.

New drug prevents flu-related inflammation and lung damage

World Pharma News - Wed, 04/10/2024 - 10:00
Infection with the influenza virus leads to lung injury through inflammation over-activation that causes collateral damage to cells required for breathing. Such damage can be life-threatening, but scientists have a new preventative treatment. A team from St. Jude Children's Research Hospital, University of Houston, Tufts University School of Medicine and Fox Chase Cancer Center created a drug that can prevent flu-induced lung injury. In a mouse model, the drug achieves a novel balance between shutting down runaway inflammation and allowing the immune system to stop the virus.

Swapping red meat for herring/sardines could save up to 750,000 lives/year in 2050

World Pharma News - Tue, 04/09/2024 - 10:00
Swapping red meat for 'forage fish', such as herring, sardines, and anchovies, could save up to 750,000 lives a year in 2050 and significantly reduce the prevalence of disability as a result of diet-related disease, suggests a data analysis published in the open access journal BMJ Global Health.

Adopting this type of diet would be especially helpful for low and middle income countries, where these fish are cheap and plentiful, and where the toll taken by heart disease, in particular, is high, say the researchers.

Does cannabis use affect cognitive decline?

World Pharma News - Mon, 04/08/2024 - 10:00
A new study by Upstate Medical University researchers shows that recreational cannabis use may offer protection against cognitive decline.

The study, done by Master of Public Health (MPH) student Zhi Chen and Professor Roger Wong, Ph.D., MPH, MSW, analyzed a large data set from the CDC and found that compared to non-users, non-medical cannabis use, such as for recreational purposes, was significantly associated with 96 percent decreased odds of subjective cognitive decline (SCD).